Last reviewed · How we verify
oxybuprocaine — Competitive Intelligence Brief
unknown
Sodium channel protein type 10 subunit alpha, Sodium channel alpha subunits; brain (Types I, II, III)
Ophthalmology
Live · refreshed every 30 min
Target snapshot
oxybuprocaine (oxybuprocaine).
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| oxybuprocaine TARGET | oxybuprocaine | unknown | Sodium channel protein type 10 subunit alpha, Sodium channel alpha subunits; brain (Types I, II, III) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- oxybuprocaine CI watch — RSS
- oxybuprocaine CI watch — Atom
- oxybuprocaine CI watch — JSON
- oxybuprocaine alone — RSS
Cite this brief
Drug Landscape (2026). oxybuprocaine — Competitive Intelligence Brief. https://druglandscape.com/ci/oxybuprocaine. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing